News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
161,808 Results
Type
Article (2713)
Company Profile (6)
Press Release (159089)
Section
Business (53974)
Career Advice (100)
Deals (10952)
Drug Delivery (5)
Drug Development (23655)
Employer Resources (10)
FDA (4230)
Job Trends (4123)
News (93055)
Policy (7552)
Tag
Academia (328)
Accelerated approval (4)
Adcomms (1)
Allergies (20)
Alliances (10631)
ALS (12)
Alzheimer's disease (316)
Antibody-drug conjugate (ADC) (21)
Approvals (4272)
Artificial intelligence (23)
Autoimmune disease (6)
Automation (1)
Bankruptcy (116)
Best Places to Work (3930)
BIOSECURE Act (2)
Biosimilars (11)
Biotechnology (4)
Bladder cancer (35)
Brain cancer (7)
Breast cancer (59)
Cancer (627)
Cardiovascular disease (30)
Career advice (92)
Career pathing (1)
CAR-T (36)
Cell therapy (115)
Cervical cancer (5)
Clinical research (20478)
Collaboration (185)
Compensation (84)
Complete response letters (3)
COVID-19 (299)
CRISPR (8)
C-suite (59)
Cystic fibrosis (31)
Data (873)
Depression (16)
Diabetes (64)
Diagnostics (1493)
Digital health (5)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (23)
Drug pricing (7)
Duchenne muscular dystrophy (29)
Earnings (27540)
Editorial (2)
Employer branding (1)
Employer resources (8)
Events (21669)
Executive appointments (192)
FDA (4695)
Friedreich's ataxia (1)
Frontotemporal dementia (3)
Funding (117)
Gene editing (26)
Generative AI (2)
Gene therapy (67)
GLP-1 (90)
Government (536)
Guidances (100)
Healthcare (4203)
Huntington's disease (2)
IgA nephropathy (10)
Immunology and inflammation (28)
Indications (8)
Infectious disease (324)
Inflammatory bowel disease (50)
Inflation Reduction Act (1)
Influenza (15)
Intellectual property (39)
Interviews (10)
IPO (5797)
IRA (3)
Job creations (421)
Job search strategy (78)
Kidney cancer (4)
Labor market (2)
Layoffs (21)
Leadership (2)
Legal (1550)
Liver cancer (16)
Lung cancer (99)
Lymphoma (50)
Machine learning (3)
Management (3)
Manufacturing (58)
MASH (38)
Medical device (3102)
Medtech (3104)
Mergers & acquisitions (5382)
Metabolic disorders (177)
Multiple sclerosis (32)
NASH (5)
Neurodegenerative disease (12)
Neuropsychiatric disorders (1)
Neuroscience (437)
NextGen: Class of 2025 (1453)
Non-profit (916)
Obesity (77)
Opinion (30)
Ovarian cancer (39)
Pain (22)
Pancreatic cancer (32)
Parkinson's disease (32)
Partnered (3)
Patents (78)
Patient recruitment (22)
Peanut (6)
People (15425)
Pharmaceutical (4)
Pharmacy benefit managers (3)
Phase I (6076)
Phase II (8790)
Phase III (7159)
Pipeline (674)
Policy (13)
Postmarket research (642)
Preclinical (2176)
Press Release (1)
Prostate cancer (30)
Psychedelics (4)
Radiopharmaceuticals (51)
Rare diseases (114)
Real estate (922)
Recruiting (2)
Regulatory (6006)
Reports (6)
Research institute (331)
Resumes & cover letters (12)
Rett syndrome (5)
RSV (5)
Schizophrenia (21)
Series A (15)
Series B (10)
Service/supplier (2)
Sickle cell disease (16)
Special edition (3)
Spinal muscular atrophy (35)
Sponsored (1)
Startups (534)
State (1)
Supply chain (11)
Vaccines (77)
Venture capitalists (3)
Weight loss (19)
Women's health (7)
Worklife (1)
Date
Today (75)
Last 7 days (398)
Last 30 days (998)
Last 365 days (9828)
2025 (3568)
2024 (10782)
2023 (12347)
2022 (13238)
2021 (14857)
2020 (13982)
2019 (12782)
2018 (7431)
2017 (7808)
2016 (6531)
2015 (8802)
2014 (6085)
2013 (4198)
2012 (4850)
2011 (5294)
2010 (4665)
Location
Africa (125)
Alabama (7)
Arizona (27)
Arkansas (2)
Asia (9930)
Australia (968)
California (2193)
Canada (281)
China (97)
Colorado (88)
Connecticut (96)
Delaware (25)
Europe (15354)
Florida (449)
Georgia (74)
Idaho (6)
Illinois (137)
India (4)
Indiana (131)
Iowa (1)
Japan (26)
Kansas (13)
Kentucky (1)
Louisiana (4)
Maine (37)
Maryland (265)
Massachusetts (1605)
Michigan (24)
Minnesota (104)
Missouri (15)
Montana (7)
Nebraska (6)
Nevada (24)
New Hampshire (32)
New Jersey (814)
New Mexico (1)
New York (674)
North Carolina (262)
North Dakota (1)
Northern California (947)
Ohio (22)
Oregon (2)
Pennsylvania (601)
Puerto Rico (7)
Rhode Island (8)
South America (173)
South Carolina (13)
Southern California (891)
Tennessee (44)
Texas (236)
United States (8129)
Utah (83)
Virginia (28)
Washington D.C. (20)
Washington State (200)
Wisconsin (1)
161,808 Results for "199".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioMidwest
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
DiaMedica Therapeutics Announces Expansion of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia.
June 26, 2024
·
13 min read
BioCapital
KeViRx, Inc. Awarded $1.99 Million
KeViRx, Inc., an innovative, early-stage pharmaceutical company, announced the receipt of $1.99 million in grant funding from the U.S. Department of Defense’s Peer Reviewed Medical Research Program.
June 11, 2024
·
3 min read
Press Releases
DiaMedica Therapeutics Announces Publication of DM199’s Mechanism of Action for the Treatment of Acute Ischemic Stroke (AIS) in the Journal Stroke
February 20, 2025
·
7 min read
Press Releases
DiaMedica Therapeutics Announces Formation of Scientific Advisor Board to Support the Development of DM199 for the Treatment of Preeclampsia
December 3, 2024
·
11 min read
Press Releases
DiaMedica Therapeutics Announces Dosing of First Patient in Phase 2 Trial of DM199 in the Treatment of Preeclampsia
November 14, 2024
·
7 min read
Drug Development
DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced the first patient being dosed in DiaMedica’s relaunch of its pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the treatment of acute ischemic stroke.
April 17, 2024
·
7 min read
Press Releases
DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia
October 9, 2024
·
8 min read
Press Releases
DiaMedica Therapeutics Releases Preeclampsia White Paper and Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
July 11, 2024
·
10 min read
Telemedicine Market to Reach $199.54Bn by 2028 to grow at a CAGR of 18.6% during 2021–2028
According to our latest study on “Telemedicine Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Type, Product & Services, Specialty, and Delivery Mode,” the market was valued at US$ 51,094.75 million in 2020 and is projected to reach US$ 199,544.64 million by 2028;
May 31, 2023
·
4 min read
Drug Development
DiaMedica Therapeutics Announces that the FDA Has Removed The Clinical Hold On DM199 Phase 2/3 Trial For Ischemic Stroke
DiaMedica Therapeutics Inc. announced today that the U.S. Food and Drug Administration (FDA) has removed the clinical hold placed on the investigational new drug application for its ReMEDy2 phase 2/3 clinical trial studying DM199 in the treatment of acute ischemic stroke (AIS) and that preparations are underway to resume the ReMEDy2 trial as soon as possible.
June 21, 2023
·
6 min read
1 of 16,181
Next
